IO Biotech

📍 Copenhagen, Denmark🗓 Founded 2015👥 68 employees💰 Last funded Sep 2019
Biotechnology Research🌐 iobiotech.com
Website LinkedIn
IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
1
Frequently asked questions
Who invested in IO Biotech?
IO Biotech has 1 investors on record on gritt.io, 1 mid-stage.
When did IO Biotech last raise funding?
The most recent investment in IO Biotech recorded on gritt.io was in September 2019.
When was IO Biotech founded?
IO Biotech was founded in 2015.
What industry is IO Biotech in?
IO Biotech operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is IO Biotech based?
IO Biotech is headquartered in Copenhagen, Denmark.